Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment

Figure 1 Historical and study chronic hepatitis C patient cohort from 1991 to 2015 in the San Cecilio University Hospital. ¹First-generation DAAs (n = 13): peg-IFN-α + RBV + telaprevir (n = 7) and peg-IFN-α + RBV + boceprevir (n = 6); ²Second-generation DAAs (n = 17): peg-IFN-α + RBV + simeprevir (n = 2), simeprevir + sofosbuvir + RBV (n = 2), simeprevir + sofosbuvir (n = 1), sofosbuvir + daclatasvir (n = 1), ledipasvir + sofosbuvir + RBV (n = 4), ledipasvir + sofosbuvir (n = 4) and ombitasvir/paritaprevir/ritonavir + dasabuvir (n = 3). DAAs: Direct-acting antivirals NVR: No virological response; IFN: Interferon; peg-IFN + RBV: Pegylated-interferon + ribavirin; RBV: Ribavirin; SVR: Sustained virological response.